Nektar Therapeutics Finalizes Terms for $150M At-The-Market Offering

summarizeSummary

Nektar Therapeutics filed a prospectus supplement to finalize the terms of its previously announced At-The-Market (ATM) equity offering, allowing it to sell up to $150 million in common stock.

check_boxKey Events

• Finalizes $150 Million At-The-Market Offering

  Nektar Therapeutics has filed a prospectus supplement to establish an At-The-Market (ATM) equity offering program, enabling the company to sell up to $150,000,000 of its common stock from time to time through sales agents Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC. This filing operationalizes the program announced in a concurrent 8-K filing.

• Capital for R&D and Clinical Development

  The net proceeds from this offering are intended for general corporate purposes, including funding research and development, clinical development costs (specifically mentioning Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing to advance its drug candidates.

• Potential Share Dilution

  The offering, if fully utilized, could result in the issuance of approximately 1,762,839 shares based on a recent market price, representing potential dilution to existing shareholders. The filing notes an immediate dilution of $54.51 per share to new investors at an assumed offering price of $85.09 per share.

auto_awesomeAnalysis

This 424B5 prospectus supplement provides the full legal framework and detailed terms for the At-The-Market (ATM) equity offering program, which was initially announced via an 8-K filing on May 8, 2026. The offering allows Nektar to sell up to $150 million of common stock from time to time through sales agents. While dilutive, this program is crucial for a clinical-stage biopharmaceutical company like Nektar to secure capital for general corporate purposes, including funding ongoing research and development, clinical trials (such as Phase 3 trials for rezpegaldesleukin), and manufacturing costs. The ability to access capital is vital for extending the company's operational runway, especially following its recent Q1 earnings report which showed a narrowed net loss and increased cash reserves. Investors should monitor the pace and pricing of future sales under this program.